QQQ0.84%

Trending

TSLA5.29%

Info

home Symbol LTRNnews

Exchange: NASDAQ·Updated 06:06 PM EDT

LTRNLantern Pharma Inc

$2.78

$0.10

(3.40%)

Today

Closed $2.84

$0.06

(2.11%)

After Hours

EarningsAug 12

Mkt Cap$37.51M

Vol47,568.00

News

all

press releases

Lantern Pharma Launches ZetaOmics an Autonomous, Intelligent Computational Biologist That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous Computational Biologist persona...

Business Wire

More News

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the...

Business Wire

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...

Business Wire

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and...

Business Wire

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

Business Wire

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning...

Business Wire

Lantern Pharma Unveils Roadmap for withZeta.ai Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm and ZetaOmics

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the companys multi-agentic A.I...

Business Wire

Lantern Pharmas predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR AI platform, today announced the expansion of predictBBB.ai into a...

Business Wire

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic...

Business Wire

Emerging Data for Lantern Pharmas Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure With No Added Toxicity

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to...

Business Wire

...